Sesame Summit 2026 – application open

Adaptam Therapeutics raises €3M in cancer immunotherapy funding

Europe’s oncology sector is witnessing a surge in innovative approaches to tackle cancer’s most persistent challenge: immune evasion. While traditional immunotherapies have shown promise, tumours continue to develop sophisticated mechanisms to hide from the body’s natural defences. Into this complex landscape steps Adaptam Therapeutics, a Spanish biotech that has secured €3 million in pre-seed funding to revolutionise how we target the immune cells that help tumours evade treatment.

Cancer immunotherapy funding attracts European venture interest

The round was led by Criteria Bio Ventures, a Barcelona-based fund known for backing early-stage life sciences companies across Southern Europe. This investment signals growing confidence in Spain’s emerging biotech ecosystem, which has historically lagged behind European powerhouses like Switzerland and the UK.

Criteria Bio Ventures’ thesis centres on identifying breakthrough therapeutic approaches before they reach mainstream attention. “Adaptam’s novel approach to targeting tumour-associated macrophages represents exactly the kind of innovative thinking we believe will define the next generation of cancer treatments,” explains a partner at the fund. The firm’s portfolio strategy focuses particularly on companies bridging fundamental research with translational medicine.

The funding landscape for European biotech has evolved considerably, with venture capital increasingly willing to back ambitious scientific approaches. This €3 million commitment reflects a broader trend of European investors backing homegrown innovation rather than simply following Silicon Valley patterns.

Targeting immune suppression in European oncology markets

Adaptam Therapeutics is developing proprietary technology to reprogram tumour-associated macrophages—immune cells that cancers co-opt to suppress immune responses. Unlike existing checkpoint inhibitors that broadly activate immune systems, Adaptam’s approach specifically targets the cellular mechanisms that tumours use to create immunosuppressive environments.

The company’s platform technology addresses a critical gap in current immunotherapy approaches. While European regulators have approved numerous checkpoint inhibitors through the European Medicines Agency, response rates remain disappointingly low for many cancer types. Adaptam’s founders believe that by focusing on macrophage reprogramming, they can unlock therapeutic potential in previously treatment-resistant tumours.

“We’re not just developing another immunotherapy—we’re targeting the fundamental mechanisms that allow tumours to create their own protective environment,” states the company’s CEO. The approach leverages decade-long research from leading European cancer institutes, positioning the company to benefit from the continent’s strong academic-industry collaboration frameworks.

The €3 million will primarily fund preclinical development and expand the company’s Barcelona-based research team. European biotech companies face unique advantages in accessing skilled researchers from the continent’s world-class universities, while benefiting from more cost-effective development compared to US counterparts.

This funding positions Adaptam within a growing cohort of European cancer immunotherapy companies that are moving beyond traditional approaches. As the European biotech sector matures, investments like this demonstrate increasing sophistication in targeting specific immune mechanisms rather than pursuing broad-based activation strategies. The success of this approach could influence how European investors evaluate next-generation oncology opportunities.

you might also like

Fundraising 4 hours ago

London-based AI laboratory Ineffable Intelligence has emerged from stealth with a $1.1 billion seed round at a $5.1 billion post-money valuation, the company confirmed on 27 April 2026. The financing is the largest seed round ever raised by a European company and one of the largest first-money-in rounds in the global history of artificial intelligence. The round was co-led by Sequoia Capital and Lightspeed Venture Partners. Participating investors included Nvidia, DST Global, Index Ventures, Google, and the UK Sovereign AI Fund, the British government’s recently established vehicle for backing strategic AI capacity on home soil. A bet on a different path to general intelligence Ineffable Intelligence was founded in 2025 by David Silver, the former Vice President of Reinforcement Learning at Google DeepMind and the principal architect of AlphaGo, AlphaZero and AlphaStar. He is joined by three further DeepMind alumni: Wojciech Czarnecki, Lasse Espeholt and Junhyuk Oh. All four have spent the past decade at the frontier of reinforcement learning research, the discipline behind some of the most consequential demonstrations of machine learning over the past ten years. The company describes its objective as building a “superlearner” — an AI system capable of acquiring knowledge directly from its own experience rather than from human-generated text or imagery. “Our mission is to make first contact with superintelligence,” Silver said in a statement accompanying the launch. “We are creating a superlearner that discovers all knowledge from its own experience, from elementary motor skills through to profound intellectual breakthroughs.” The framing is a deliberate departure from the dominant industry trajectory. Most leading AI laboratories, including OpenAI, Anthropic and Google DeepMind itself, have built large language models trained primarily on the corpus of the internet, then refined that training with human feedback. Ineffable’s wager is that the marginal returns on scaling text-based pretraining are diminishing and that the next leap in capability will come from agents that learn endlessly from the consequences of their own actions, in much the same way AlphaZero learnt the game of Go without studying any human matches. Why $1.1 billion at seed The size of the round is unusual even by the inflated standards of the 2026 AI capital cycle. Two factors appear to explain it. First, frontier reinforcement learning at the scale Ineffable describes is computationally extraordinarily expensive: the company will need to operate vast simulation environments and train very large models against them, an undertaking that consumes capital at a rate closer to physical R&D than to traditional software. Second, the round signals a strategic move by Europe’s investor and policy ecosystems to retain the most ambitious AI researchers on the continent. The presence of the UK Sovereign AI Fund alongside Sequoia, Lightspeed and Nvidia is the clearest expression of that intent. The British government has publicly framed the investment as a bet on breakthrough AI that “can discover new knowledge”, positioning the country as a willing co-investor in domestic frontier laboratories. For Ineffable, the implication is access not only to capital but to compute, regulatory engagement and the still-resilient academic talent base around UCL, Oxford, Cambridge and Imperial. Founder pledge of historic scale Alongside the funding announcement, Silver disclosed that he is committing 100 per cent of any personal proceeds from his Ineffable equity to charity via the Founders Pledge network — described by the organisation as the largest pledge in its history. At the round’s $5.1 billion valuation, that commitment could ultimately exceed several billion dollars if the company succeeds. It is a meaningful gesture in a sector where the reputational stakes around concentrated AI wealth are escalating, and one likely to be referenced in subsequent founder-led commitments. Implications for the European AI landscape Ineffable’s emergence reshapes the European AI map in three concrete ways. It establishes London as the home of the continent’s largest-ever seed-stage company, complicating Paris’s recent narrative of frontier-AI primacy after Mistral’s earlier rounds. It validates a thesis — that reinforcement learning, not transformer scaling, is the next frontier — that has lately been losing capital share to language-model incumbents. And it confirms that the UK government is now willing to act as a balance-sheet co-investor in domestic AI laboratories, a posture much closer to the French model than to the predominantly grant-based regimes elsewhere in Europe. The execution risk is non-trivial. Reinforcement learning at frontier scale has historically required years of careful environment design before producing competitive systems, and Ineffable’s “first contact” framing sets a high bar against which it will be judged. But for now, with a billion dollars on the balance sheet, four of the discipline’s most accomplished researchers in the founding team and a sovereign co-investor at its back, Ineffable Intelligence is the most heavily resourced new entrant in the European AI cycle. Sesamers covers European fundraising rounds across deeptech, fintech and AI. Source: tech.eu.

Fundraising 5 days ago

Belfast's Cloudsmith has raised $72M Series C led by TCV, with Insight Partners participating, to expand its artifact management platform and secure the AI-era software supply chain.

Fundraising 5 days ago

Berlin’s VREY has raised €3.3M seed led by Rubio Impact Ventures to roll out rooftop solar software for Germany’s multi-family buildings.

Subscribe to
our Newsletter!

Stay at the forefront with our curated guide to the best upcoming Tech events.